ArticleEuropean journal of nuclear medicine and molecular imaging2022
ImmunoPET of trophoblast cell-surface antigen 2 (Trop-2) expression in pancreatic cancer.
Article in European journal of nuclear medicine and molecular imaging, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 47 citations in OpenAlex.
- 68Ga-MY6349 PET/CT imaging to assess Trop2 expression in multiple types of cancer.The Journal of clinical investigation · 2024Trial
- Molecular Imaging in Pancreatic Cancer: Current Applications and Future Perspectives.Pharmaceuticals (Basel, Switzerland) · 2026Review
- A Phase II study of SHR-A1921, a TROP2-targeted antibody-drug conjugate, in patients with recurrent or metastatic salivary gland carcinoma.NPJ precision oncology · 2026Article
- Trop-2.2-Directed Radioimmunotherapy with 177Lu, 225Ac, and 212Pb in a Pancreatic Cancer Model.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Cell surface oncofetal antigens in prostate cancer: therapeutic potential and radioligand targeting.EJNMMI research · 2026Review
- Legumain-Cleavable Top1i Antibody-Drug Conjugates without Self-Immolative Spacers Demonstrate Potent Antitumor Activity.Journal of medicinal chemistry · 2025Article
- Noninvasive Evaluation of Trop2 Expression UsingMolecular pharmaceutics · 2025Article
- [European journal of nuclear medicine and molecular imaging · 2025Article
- Preclinical evaluation of zirconium-89 labeled anti-Trop2 antibody-drug conjugate (Trodelvy) for imaging in gastric cancer and triple-negative breast cancer.European journal of nuclear medicine and molecular imaging · 2025Article
- Noninvasive molecular imaging using anti-Trop-2 aptamer for targeted therapy of small cell lung cancer.Journal of nanobiotechnology · 2025Article
- Pre-treatment [18F]FDG PET/CT biomarkers for the prediction of antibody-drug conjugates efficacy in metastatic breast cancer.European journal of nuclear medicine and molecular imaging · 2025Article
- TROP2-targeted molecular imaging: a promising tool for precision oncology.American journal of nuclear medicine and molecular imaging · 2025Review
- Trop2-targeted immunoPET ligands.American journal of nuclear medicine and molecular imaging · 2025Article
- Recent Advances in Small Molecular PET Tracers for Pancreatic Cancer Diagnosis: Preclinical Stage.Mini reviews in medicinal chemistry · 2025Review
- Role of molecular imaging in prognosis, diagnosis, and treatment of gastrointestinal cancers: An update on new therapeutic methods.World journal of methodology · 2024Review
- Trop2-Targeted Molecular Imaging in Solid Tumors: Current Advances and Future Outlook.Molecular pharmaceutics · 2024Review
- Novel Anti-Trop2 Nanobodies Disrupt Receptor Dimerization and Inhibit Tumor Cell Growth.Pharmaceutics · 2024Article
- Preclinical evidence for the use of anti-Trop-2 antibody-drug conjugate Sacituzumab govitecan in cerebral metastasized castration-resistant prostate cancer.Cancer medicine · 2024Article
- Development and application of a fully automatic multi-function cassette module Mortenon M1 for radiopharmaceutical synthesis.Annals of nuclear medicine · 2024Article
- Functional requirement of alternative splicing in epithelial-mesenchymal transition of pancreatic circulating tumor.Molecular therapy. Nucleic acids · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 2 countries.
Funding
Abstract
purposeWithout a standard test for pancreatic carcinomas, this highly lethal disease is normally diagnosed at its advanced stage, leading to a low survival rate of patients. Trophoblast cell-surface antigen 2 (Trop-2), a transmembrane glycoprotein, is associated with cell proliferation and highly expressed in most of solid epithelial tumors, including pancreatic cancer. A non-invasive method of imaging Trop-2 would greatly benefit clinical diagnosis and monitoring of pancreatic cancer. In the current study,
methodsAF650 was conjugated with desferrioxamine (DFO) and then radiolabeled with
resultsBxPC-3 cells expressed high levels of Trop-2, while AsPC-1 and MIA PaCa-2 cells expressed low levels of Trop-2. Additionally,
conclusions
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.